ProductsDistribution Products

ELIGARD

Therapeutic indication:

ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

 

  • Composition: Leuprolide Acetate 22.5mg Leuprolide Acetate 45mg
  • Method of administration: Subcutaneous
  • Manufacturer: Tolmar Pharmaceuticals Inc., USA
ELIGARD - Product Logo
ELIGARD - Product Image

Join Our Mailing List

Sign up to receive Email updates from Kamada

Latest News

Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
May. 8, 2024